anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: biotechnology, molecular biology, medicine. SUBSTANCE: method involves detection of polymorphous variants of gene HLA-H (Cys282Tyr and His63Asp) based on polymorphism method of restriction fragments length. Method involves the use of primers flanking gene sites where corresponding mutations are localized and introduction of restriction endonuclease Ksp 221 site in one of primers in the case of mutation His63Asp to obtain distinct differentiation of homo- and heterozygous genotypes. Method involves amplification of DNA of gene HLA-H containing sites of possible location of mutations Cys282Tyr and His63Asp with primers 5'-CTACC-CCCAG- -AACAT-CACCA-3' and 5'-CTCCA-ATGAC-TAGGG-TGCCA-3' in the case of mutation Cys282Tyr and primers 5'-CCCTC-TCCAC-ATACC-CTTGC- -TG-3' and 5'-AAGCT-TTGGG-CTACG-TGGAT-GATCA-G-3' in the case of mutation His63Asp followed by hydrolysis of the first of indicated amplifiers with restriction endonuclease Rsa I and the second one - with restriction endonuclease Ksp 221. Products obtained after hydrolysis of amplifiers are analyzed in polyacrylamide gel. Method ensures to screen large mass of DNA samples to detect persons showing predisposition to hemochromatosis. Diagnosis of this disease carrying out before organic damage of visceral organs ensures to treat these patients successfully and prevent the development of cirrhosis and liver cancer. EFFECT: simplified method, increased precision of diagnosis. 2 dwg, 1 ex
This study is a multisite, randomized, double-blind, placebo-controlled, phase 2/3 study of MG01CI (1400 mg once daily) for 6 weeks compared with placebo in a 1:1 ratio of 300 adults with ADHD. The study comprises a Screening Visit at which initial assessment will be made and then a Washout Period during which prospective subjects must discontinue ADHD medication for 14 days (for psychotropic medications other than fluoxetine) or for 28 days (for fluoxetine) before randomization into the study. The Washout Period is 14 days, but may be extended to 28 days for a fluoxetine washout. Subjects requiring either a 14-day or a 28-day Washout Period will have an Interim Visit (off drug) on or about Day -8 (Day -10 to Day -3) for CAARS-Inv assessment after the Washout Period. The Baseline CAARS Inv assessment will be conducted on Day 0. If there is a ≥25% change in the CAARS-Inv results between the Interim Visit (off drug) assessment and the Baseline assessment, or if the subject does not return for the Baseline CAARS-Inv assessment, the subject will not be randomized. For subjects not needing washout, if there is a ≥25% change in the CAARS-Inv results between the Screening Visit assessment and the Baseline assessment, or if the subject does not return for the Baseline CAARS-Inv assessment, the subject will not be randomized. Following the Washout Period for those requiring a washout, or following the Screening Visit for those subjects who do not require a washout, eligible subjects will undergo baseline assessments and be randomized on Day 0 to MG01CI 1400 mg or to matching placebo and begin the Double-blind Treatment Period. The Double-blind Treatment Period will be 6 weeks in duration. There will be a 2-week Follow-up Period after the last dose of study treatment or early termination.
OBJECTIVE: Amphetamine prescribing has increased in the United States in recent years. Previous research identified an increased risk of incident psychosis with prescription amphetamines. The purpose of this study was to examine the impact of dose levels of prescription amphetamines on the risk of this rare but serious adverse outcome.
METHODS: A case-control study using electronic health records was conducted to compare the odds of incident psychosis or mania with past-month exposure to prescription amphetamines. Case subjects were patients ages 16-35 hospitalized at McLean Hospital for incident psychosis or mania between 2005 and 2019. Control subjects were patients with an initial psychiatric hospitalization for other reasons, most commonly depression and/or anxiety. Amphetamine doses were converted to dextroamphetamine equivalents and divided into terciles. Secondary analyses evaluated the odds of psychosis or mania with methylphenidate use.
RESULTS: Among 1,374 case subjects and 2,748 control subjects, the odds of psychosis and mania were increased for individuals with past-month prescription amphetamine use compared with no use (adjusted odds ratio=2.68, 95% CI=1.90-3.77). A dose-response relationship was observed; high doses of amphetamines (>30 mg dextroamphetamine equivalents) were associated with 5.28-fold increased odds of psychosis or mania. Past-month methylphenidate use was not associated with increased odds of psychosis or mania compared with no use (adjusted odds ratio=0.91, 95% CI=0.54-1.55).
CONCLUSIONS: Although use of hospitalized control subjects excludes individuals with less severe disease, leading to selection bias, the study results suggest that caution should be exercised when prescribing high doses of amphetamines, with regular screening for symptoms of psychosis or mania.
The degeneration that occurs in the osteoarthritis of the knee joint leads to the loss of proprioception, resulting in the misalignment of the mechanoreceptors in that region, the joint stabilization is impaired, the muscles do not fulfill the protective role and the joint neuromuscular is inadequate for control. Neuromuscular control is the subcortical activity of effector structures against stimulation with mechanoreceptor, visual, and vestibular affinities. Proprioception, kinesthesia, sensation of joint position, visual and vestibular information constitute sensory data; functional motor patterns, dynamic joint stability and reactive neuromuscular control motor efferent response definitions. Disturbance of neuromuscular control of the muscles also affects walking and balance with abnormal weight transfer. There are many ways to treat knee osteoarthritis such as patient education, weight control, different physical therapy modalities (hot, cold, electrotherapy, deep heat), exercise, pharmacological treatments (topical, systemic, intraarticular). There is no radical treatment of osteoarthritis to restore structural changes; but with the treatment applied, findings such as pain and loss of function of the individual can be reduced and the patients become more independent in daily life activities. Surgical treatment is the last resort in osteoarthritis. In osteoarthritis( OA), there is no pharmacological method to treat the deformed joint structure that will change the course of the disease. This situation significantly increases the importance of rehabilitation in the treatment of osteoarthritis. The aim of neuromuscular rehabilitation that reestablish and regulated features such as dynamic joint stability, reactive neuromuscular control, functional motor patterns. Rehabilitation programs created for this purpose include balance exercises, strengthening exercises, postural control, functional exercises, postural orientation, flexibility, agility, plyometric exercises, spore-specific exercises. neuromuscular exercise program includes 7 parameters including functional mobility, functional stability, sensorimotor system training, proprioceptive neuromuscular facilitation training techniques, plyometric exercises, reactive neuromuscular system training, technical training. Main purpose of this study is that the effect of neuromuscular exercise program on physical activity, functionality and balance in patients with knee osteoarthritis.
The training group, based on motivational strategies were performed and a moderate intensity training (8 to 12 repetitions). The load was increased: during the 12 weeks from 65% 1-RM to 80% 1-RM, performing individual more than the prescribed number of repetitions (12 repetitions). A 1-2 minutes resting period was allowed between sets. There was no attempt to control the velocity of the repetitions performed. Prior to each training session, the volunteers performed a specific warmup, consisting of 10 repetitions with approximately 50% of the load used in the first and second exercises of the training session. A total of 36 sessions were performed during the training period. This group was compared with no interventions subjects.
BACKGROUND: The genetic signatures associated with the susceptibility to nontuberculous mycobacterial pulmonary disease (NTM-PD) are still unknown. In this study, we performed RNA sequencing to explore gene expression profiles and represent characteristic factor in NTM-PD.
METHODS: Peripheral blood samples were collected from patients with NTM-PD and healthy individuals (controls). Differentially expressed genes (DEGs) were identified by RNA sequencing and subjected to functional enrichment and immune cell deconvolution analyses.
RESULTS: We enrolled 48 participants, including 26 patients with NTM-PD (median age, 58.0 years; 84.6% female), and 22 healthy controls (median age, 58.5 years; 90.9% female). We identified 21 upregulated and 44 downregulated DEGs in the NTM-PD group compared to those in the control group. NTM infection did not have a significant impact on gene expression in the NTM-PD group compared to the control group, and there were no differences in the proportion of immune cells. However, through gene ontology (GO), gene set enrichment analysis (GSEA), and protein-protein interaction (PPI) analysis, we discovered that PARK2 is a key factor associated with NTM-PD. The PARK2 gene, which is linked to the ubiquitination pathway, was downregulated in the NTM-PD group (fold change, - 1.314, P = 0.047). The expression levels of PARK2 remained unaltered after favorable treatment outcomes, suggesting that the gene is associated with host susceptibility rather than with the outcomes of infection or inflammation. The area under the receiver operating characteristic curve for the PARK2 gene diagnosing NTM-PD was 0.813 (95% confidence interval, 0.694-0.932).
CONCLUSION: We identified the genetic signatures associated with NTM-PD in a cohort of Korean patients. The PARK2 gene presents as a potential susceptibility factor in NTM-PD .
For a 22-week period, participants will be asked to follow a portion-controlled diet which will include individualized diet plans that reduce daily energy intake by 500 kcal for overweight participants, and keep carbohydrate intake reasonably stable over time. It will derive 50% of total energy from carbohydrates, 20% from protein, and less than 30% from fat (≤7% saturated fat), with less than 200 mg/day of cholesterol/day.
NEW MATERIAL:A compound expressed by formula I (B is nucleic acid base derivative; R is H, acyl or phosphate group or protecting group). EXAMPLE:(+ or -)-9-(1,6-Dihydroxy-3-hexyl)adenine. USE:An antiviral agent and anticancer agent. PREPARATION:A compound expressed by formula II (X is eliminating group) is reacted with a nucleic acid base derivative (e.g. adenine) as necessary in the presence of a base catalyst (e.g. potassium carbonate), in a solvent such as DMF at 0 deg.C to temperature capable of refluxing the solvent to afford a compound expressed by formula III (B<1> is nucleic acid base derivative which may be protected). Then, as necessary, a protecting group thereof is removed or replaced by other protecting group to provide the compound expressed by formula I.
PC1-CTT polypeptides for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are provided and can be or include PC1-CTT (SEQ ID NO:1) or a functional fragment or variant thereof. In some embodiments, the PC1-CTT polypeptide is a fusion protein or conjugate further including a functional element such as a protein transduction domain, fusogenic polypeptide, targeting signal, or expression and/or purification tag. Nucleic acids encoding the disclosed PC1-CTT polypeptides and other therapeutic proteins are also provided. In some embodiments, the nucleic acid encodes a TOP or TOP-like motif. The nucleic acids can be RNA or DNA, and can be, for example, a vector such as a plasmid or viral vector, or an mRNA. Methods of treatment are provided and typically include administering a subject in need thereof an effective amount of a disclosed polypeptide or nucleic acid.
PURPOSE: To obtain an agent for the treatment of diffuse intravascular coagulation syndrome to be used in the form of intravenous drip by using hirudin as an active component. CONSTITUTION: The objective agent contains 0.005-0.038mg/ml (50-380 ATU/ml) of hirudin or a gene-recombinant hirudin derivative expressed by formula as an active component and is formed in the form of intravenous drip to get a daily administration rate of 500-1,000ml. It is especially preferable from the balance of the drug effect and the side effect by administering hirudin or its derivative by intravenous drip at a rate of 0.005mg/kg (50 ATU/kg) to 0.01mg/kg (100 ATU/kg) per hour. The administration rate of the agent in the case of treating diffuse intravascular coagulation syndrome is 1/10 to 1/5 of conventional intravenous drip. It has extremely low bleeding risk and high therapeutic effect. 1 ATU corresponds to the amount of hirudin to inhibit (neutralize) 1 unit (IU) of thrombin.
A shield, when coupled to a tracker device that is worn by an individual, reduces interfering signals originating from the human body that can adversely impact the detection of signals transmitted by the tracker device. The shield can include multiple layers of components. Specifically, the shield includes a base component that is attached to an adhesive element on the first side of the base and covered by a removable backing. Furthermore, the base, through a second side of the base, is attached to a first non-conductive element, which is further coupled to a second non-conductive element. Each of the non-conductive elements attenuates interfering signals that originate from the human body and therefore, enables the detection of signals transmitted by the patient tracking system. For example, in view of the reduced interference signals, a RF signal transmitted by the patient tracking system can be detected at remote distances.
Self-assembling peptides or self-assembling peptidomimetics ("SAPs") can treat inflammation or inflammatory diseases, or alleviate one or more symptoms of diseases and disorders associated with undesirable inflammation. Topical and injectable compositions of SAPs for topical administration to sites of inflammation to reduce or prevent symptoms of inflammatory diseases and disorders are described. These compositions comprise one or more SAPs in an amount and concentration effective to reduce or prevent one or more symptoms of the undesired inflammation. The SAP may be assembled before or after the composition is applied. The SAP forms structures within or on the body surface that prevent and/or reduce symptoms associated with inflammatory and other dysregulated immune processes. These peptides may assemble upon contact with bodily fluids (e.g., synovial fluid), or may be contacted with an ionic solution to begin assembly.
Endoscopic submucosal resection (EMR) or submucosal dissection (ESD) for gastrointestinal lesions were used to treat early gastrointestinal cancer or large benign polyps, and their complete resection rates were high, which greatly reduce unnecessary surgical operations. However, after endoscopic resection of mucosal/submucosal lesions, large mucosal/submucosal defects may be created. These defects may cause more delayed postoperative adverse events (bleeding, perforation). The use of clips to completely seal the mucosal defect after gastrointestinal mucosal/submucosal lesion resection can significantly reduce postoperative adverse events, but the rate of incomplete mucosal defects closure is high. The surgical sutures combined with clips to close the mucosal defect after surgery significantly increased the complete closure rates of the post-EMR/ESD mucosal/submucosal defect. This study intends to further determine its safety and effectiveness through a clinical randomized controlled study, and standardize indications and contraindications. A total of 62 enrolled patients were allocated into two groups, 31 patients were set as a treatment group using continuous suture technique to close post-EMR/ESD mucosal/submucosal defects, the rest patients were set as a control group using clips. The safety and effectiveness of continuous sutures and clips to clamp the post-EMR/ESD mucosal/submucosal defect were compared in the two groups. The primary outcome was complete mucosal/submucosa defects closure rates. The secondary outcomes were the closure time, closure speed, and immediate bleeding during the operation as well as delayed bleeding, delayed perforation, and polyps syndrome after resection.
Sepsis-associated encephalopathy (SAE), one of the common complications of sepsis, is associated with higher ICU mortality, prolonged hospitalization, and long-term cognitive decline. Sepsis can induce neuroinflammation, which negatively affects hippocampal neurogenesis. Dexmedetomidine has been shown to protect against SAE. However, the potential mechanism remains unclear. In this study, we added lipopolysaccharide (LPS)-stimulated astrocytes-conditioned media (LPS-CM) to neural stem cells (NSCs) culture, which were pretreated with dexmedetomidine in the presence or absence of the α2-adrenoceptor antagonist yohimbine or the α2A-adrenoceptor antagonist BRL-44408. LPS-CM impaired the neurogenesis of NSCs, characterized by decreased proliferation, enhanced gliogenesis, and declined viability. Dexmedetomidine alleviated LPS-CM-induced impairment of neurogenesis in a dose-dependent manner. Yohimbine, as well as BRL-44408, reversed the effects of dexmedetomidine. We established a mouse model of SAE via cecal ligation and perforation (CLP). CLP-induced astrocyte-related neuroinflammation and hippocampal neurogenesis deficits, accompanied by learning and memory decline, which were reversed by dexmedetomidine. The effect of dexmedetomidine was blocked by BRL-44408. Collectively, our findings support the conclusion that dexmedetomidine can protect against SAE, likely mediated by the combination of inhibiting neuroinflammation via the astrocytic α2A-adrenoceptor with attenuating neuroinflammation-induced hippocampal neurogenesis deficits via NSCs α2A-adrenoceptor.
Previous studies have reported swimming, atopic dermatitis, and filaggrin (FLG) gene mutations as risk factors for molluscum contagiosum (MC) infection. FLG gene mutations impair skin barrier function. The aim of this study was to determine the impact of FLG mutations on the incidence and clinical features of MC. We used data from 2036 children who participated in the Yamanashi Adjunct Study of the Japan Environment and Children's Study, a prospective, birth cohort study. A questionnaire for caregivers (when children were 4 and 8 years of age) asked about clinical features including previous MC incidence and treatment, number of MC lesions at first visit, and time to resolution. Participants underwent genotyping to detect six FLG mutations that are common in the Japanese population. A logistic regression model was used to analyze the association between MC incidence and FLG mutations, adjusted for potential confounders. The cumulative incidence of MC at age 8 years was 47.1%. Among participants with a history of MC, 67.6% had undergone curettage. FLG mutation was a significant risk factor for MC incidence (adjusted odds ratio [aOR] 1.69, 95% confidence interval [CI] 1.18-2.42). Swimming and atopic dermatitis were also significant risk factors for MC. There was no significant association between FLG mutation and the number of MC lesions at the first visit or the time to resolution of lesions. FLG mutation is a risk factor for MC incidence; however, FLG mutations do not affect the number of MC lesions at presentation or the time to resolution.
PURPOSE: A cosmetics containing an aloe vera gel and a quasi drug composition are provided to effectively extract an active ingredient without any skin problem due to remaining organic solvent by not destroying the active ingredient as working on a low temperature. CONSTITUTION: A functional cosmetics composition containing an aloe vera gel extracts under 38 degree Celsius and 198-200 atmospheric pressure using a supercritical carbon dioxide from an aloe leaf. The supercritical carbon dioxide aloe vera gel manufacture comprises the following steps. First, the aloe leaf is washed with purified water and natural dried in the shade, and crushed. The crushed aloe leaf is placed in the reactor for 38 degree Celsius to inject carbon dioxide and increase the pressure up to 200 atmospheric pressure. 4 hours are maintained and as lowering the pressure to 1atp, the carbon dioxide dissolved aloe vera gel is obtained.
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for a tumor-associated antigen (TAA) and at least one binding site for an antigen expressed on an effector T cell, NK cell, monocyte or neutrophil. The bispecific antibodies are of use for inducing an immune response against a TAA-expressing tumor. The methods may comprising administering the bispecific antibody in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC. In preferred embodiments, the checkpoint inhibitor is a chimeric or humanized anti-PD1 antibody as described herein.
Syncope is a symptom in which transient loss of consciousness occurs as a consequence of a self-limited, spontaneously terminating period of cerebral hypoperfusion. Many circulatory disturbances (e.g. brady- or tachyarrhythmias, reflex cardioinhibition-vasodepression-hypotension) may trigger a syncope or near-syncope episode, and identifying the cause(s) is often challenging. Some syncope may involve multiple etiologies operating in concert, whereas in other cases multiple syncope events may be due to various differing causes at different times. In this communication, we address the current understanding of the principal contributors to syncope pathophysiology including examination of the manner in which concepts evolved, an overview of factors that constitute consciousness and loss of consciousness, and aspects of neurovascular control and communication that are impacted by cerebral hypoperfusion leading to syncope. Emphasis focuses on 1) current understanding of the way transient systemic hypotension impacts brain blood flow and brain function; 2) the complexity and temporal sequence of vascular, humoral, and cardiac factors that may accompany the most common causes of syncope; 3) the range of circumstances and disease states that may lead to syncope; and 4) clinical features associated with syncope and in particular the reflex syncope syndromes.
The invention belongs to the field of drug or health care product, and more specifically relates to a gynura formosana Kitam. total flavonoids extract, a preparation method thereof, and applications of the gynura formosana Kitam. total flavonoids extract in treating alcoholic fatty liver. The gynura formosana Kitam. total flavonoids extract comprises, by weight, 80 to 85% of rutin. Drug effect experiments are carried out taking zebra fish alcoholic fatty liver models as experimental models. It is shown by experiment results that the gynura formosana Kitam. total flavonoids extract possesses protective effect on alcoholic fatty liver, is capable of protecting livers, and can be taken as a potential drug used for treating alcoholic liver injury. According to the preparation method, after extraction, a composite enzyme is composed of enzymes of specific composition and specific ratio, and is used for enzymatic hydrolysis; and in addition, macroporous resin extraction condensation and macroporous resin separation purifying are adopted. The HPLC purity of rutin in the gynura formosana Kitam. total flavonoids extract is capable of reaching 80 to 85%.